scholarly journals Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
A Righi ◽  
M Gambarotti ◽  
M Sbaraglia ◽  
T Frisoni ◽  
D Donati ◽  
...  
2013 ◽  
Vol 95-B (3) ◽  
pp. 384-390 ◽  
Author(s):  
J. D. Stevenson ◽  
A. Jaiswal ◽  
J. J. Gregory ◽  
D. C. Mangham ◽  
G. Cribb ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Monique J. L. Mastboom ◽  
Floortje G. M. Verspoor ◽  
Hans Gelderblom ◽  
Michiel A. J. van de Sande

In Tenosynovial Giant Cell Tumours (TGCT), previously named Pigmented Villonodular Synovitis (PVNS), a distinction is made between a single nodule (localized-type) and multiple nodules (diffuse-type). Diffuse-type is considered locally aggressive. Onset and extermination of this orphan disease remain unclear. Surgical resection is the most commonly performed treatment. Unfortunately, recurrences often occur (up to 92%), necessitating reoperations and adjuvant treatments. Once all treatments fail or if severe complications occur, limb amputation may become unavoidable. We describe four cases of above-knee amputation after TGCT diagnosis.


10.3823/2360 ◽  
2017 ◽  
Vol 10 ◽  
Author(s):  
Hasna Salhi ◽  
Olfa Jaidane ◽  
Jamel Ben Hassouna ◽  
Tarek Ben Dhieb ◽  
Monia Hechiche ◽  
...  

Tenosynovial giant cell tumors (TGCT) are a group of generally benign intra-articular and soft tissue tumors with common histological features. TGCT is also known as pigmented villonodular synovitis. There are localized and diffuse forms. Localized types include giant cell tumors of tendon sheath and localized pigmented villonodular synovitis, whereas diffuse types encompass conventional pigmented villonodular synovitis and diffuse type giant cell tumor. Localized tumors are generally indolent, whereas diffuse tumors are locally aggressive. In this article, we report the case of a diffuse-type extra-articular TGCT found in the left thigh of a 73-year-old woman who presented with a painless but gradually progressive swelling in the left thigh since eighteen months. On examination, there was a soft cystic swelling measuring 22 cm. The swelling was fixed to the underlying soft tissues. She had a Computed Tomography scan of the left thigh showing a mass of fluid density, well encapsulated between the muscles of the thigh, measuring 20x10 cm of major axes, compressing the femoral vessels without invading them. The patient had a complete marginal resection of the tumor. The immune-histopathological findings were consistent with those of a diffuse type of Giant Cell Tenosynovial Tumor. At 18 months follow-up, the patient is asymptomatic with no evidence of disease recurrence.  The extra-articular diffuse type TGCT is more aggressive than the localized type. Although these tumors are benign in the majority of cases, malignant transformation has been reported. Therefore, close follow-up is recommended after tumor excision.


2018 ◽  
Vol 100-B (7) ◽  
pp. 984-988 ◽  
Author(s):  
Y. Gortzak ◽  
M. Vitenberg ◽  
T. Frenkel Rutenberg ◽  
Y. Kollender ◽  
S. Dadia ◽  
...  

Aims Intra-articular 90Yttrium (90Y) is an adjunct to surgical treatment by synovectomy for patients with diffuse-type tenosynovial giant-cell tumour (dtTGCT) of the knee, with variable success rates. Clinical information is, however, sparse and its value remains unclear. We investigated the long-term outcome of patients who underwent synovectomy with and without adjuvant treatment with 90Yttrium. Patients and Methods All patients with dtTGCT of the knee who underwent synovectomy between 1991 and 2014 were included in the study. Group A patients underwent synovectomy and an intra-articular injection of 90Yttrium between six and eight weeks after surgery. Group B patients underwent surgery alone. Results There were 34 patients in group A and 22 in group B. Recurrence of dtTGCT was identified by MRI, which was undertaken in patients with further symptoms. At a mean follow-up of 7.3 years (2.5 to 25.4), there was residual disease in 15 patients in group A and 11 in group B (p < 0.363). The mean Musculoskeletal Tumor Society (MSTS) score at final follow-up was 85% and 83%, respectively (p < 0.91). Conclusion There were no significant differences in outcome between patients treated surgically for dtTGCT of the knee with or without an adjuvant intra-articular injection of 90Yttrium. We were unable to provide conclusive evidence of any benefits derived from the adjuvant treatment. Cite this article: Bone Joint J 2018;100-B:984–8.


2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Erdem Degirmenci ◽  
AbdullahAlper Sahin ◽  
YunusEmre Bulum ◽  
Mehmet Gamsizkan ◽  
Zafer Orhan

Sign in / Sign up

Export Citation Format

Share Document